RareResearch.AI
← Back to atlas

C360Y

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card
CysteineTyrosine at position 360 · Transmembrane helix 2 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type C360 — hydrogen bond to V364
Fullscreen ↗
DynaMut2 mutant · C360Y
Mutant Y360 — hydrogen bond contact to V633 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost16 gained10 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondS356S356Preserved
Hydrogen bondK363K363Preserved
Hydrogen bondV364V364Preserved
Hydrogen bondH407Gained
Hydrogen bondS411Gained
Hydrogen bondV633Lost
Hydrogen bondL637Gained
Polar contactS356S356Preserved
Polar contactM357M357Preserved
Polar contactV358V358Preserved
Polar contactL362Gained
Polar contactK363K363Preserved
Polar contactV364V364Preserved
Polar contactH407Gained
Polar contactS411Gained
Polar contactV633Gained
Polar contactL637Gained
Aromatic / πH407Gained
Aromatic / πF408Gained
CarbonylK363Gained
Van der WaalsL362Gained
Van der WaalsK363Gained
Van der WaalsH407H407Preserved
HydrophobicP404Gained
HydrophobicH407Gained
HydrophobicF408F408Preserved
HydrophobicV633Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-1.05kcal/mol
Destabilising — moderate
AlphaMissense
0.980
likely pathogenic
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsOptic atrophy; Wolfram syndrome 1; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram-like syndrome; Cataract 41
Population frequency (gnomAD v4)Low frequency · AF 0.020%
cDNA changec.1079G>A
ClinVar accessionVCV000374398
Last evaluated2025/11/18 00:00

Observed in the general population.

Full Variant Card

WFS1 Wolframin — C360Y Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Cysteine → Tyrosine at position 360. Transmembrane helix 2. ClinVar Uncertain significance, AlphaMissense 0.980, DynaMut2 ΔΔG -1.05 kcal/mol (destabilising).


Identity

FieldValue
VariantC360Y (p.Cysteine360Tyrosine)
DNA changec.1079G>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV000374398
Amino acid changeCysteine (C) → Tyrosine (Y)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 36090.12 — well-folded
DomainTransmembrane helix 2
Position contextInside Transmembrane helix 2 · position 360 is bilayer-embedded
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 360 sits in a transmembrane helix (Transmembrane helix 2). Wolframin has eleven such helices anchoring it in the ER membrane; substitutions inside the bilayer-embedded segments can disrupt helix packing, lipid contacts, and the overall ER topology of the protein. The wild-type residue is thiol (cysteine — disulfide-capable, free -SH); the mutant is aromatic with hydroxyl (tyrosine — H-bond donor/acceptor). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9797
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-1.05 (Destabilising)
Job ID178092094476
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092094476

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2025/11/18 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeC360Y is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Optic atrophy
  • Wolfram syndrome 1
  • Autosomal dominant nonsyndromic hearing loss 6
  • Type 2 diabetes mellitus
  • Wolfram-like syndrome
  • Cataract 41

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.05 < 2 kcal/mol (fold intact) + AlphaMissense 0.980 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.05 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.980. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • C360Y_molstar_viewer.html — interactive 3D viewer (auto-highlights position 360 with ball-and-stick + neighbors within 5Å)
  • C360Y_variant_card.md — this card (source of truth)
  • C360Y_variant_card.html — styled printable card
  • C360Y_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • C360Y_wildtype_interactions.pse / C360Y_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the C360Y PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download C360Y PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.